AstraZeneca PLC (LON: AZN)

Market Cap	154.55B
Revenue (ttm)	38.20B
Net Income (ttm)	4.85B
Shares Out	1.55B
EPS (ttm)	3.10
PE Ratio	32.20
Forward PE	13.74
Dividend	2.34 (2.33%)
Ex-Dividend Date	Aug 8, 2024

Volume	1,007,392
Open	9,867
Previous Close	9,969
Day's Range	9,867 - 10,088
52-Week Range	9,461 - 13,388
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial numbers in USD